Moein Moghimi

Moghimi completed his secondary education at D'Overbroeck's College in Oxford, United Kingdom. He pursued a bachelor's degree in biochemistry at the University of Manchester and graduated with honors in 1985. He completed his PhD in liposome immunobiology/biochemistry in 1989 at the Biochemistry Department of the Charing Cross Hospital Medical School at Imperial College London (then University of London) under the mentorship of Harish M. Patel.{{Cite web |title=Invited speakers |url=https://cespt.org/invited-speakers/ |website=CESPT 2023}}

He then joined Stanley Stewart Davis' laboratory at the Department of Pharmaceutical Sciences, University of Nottingham for postdoctoral training in advanced drug delivery system engineering. Later he became a University Research Fellow at University of Nottingham.

Moghimi was the senior lecturer of Biopharmacy and Molecular Pharmaceutics at the School of Pharmacy, University of Brighton from 1998 until 2008. From 2008 until 2010, he was honorary professor of nanomedicine at the Multidisciplinary Research Center, Shantou University.{{Cite web |title=Staff Profile School of Pharmacy Newcastle University |url=https://www.ncl.ac.uk/pharmacy/people/profile/seyedmoghimi.html |website=ncl.ac.uk}}

He was also a full affiliate professor at the Methodist Research Institute, Houston Methodist Hospital systems in Texas between 2013 and 2017.{{Cite web |title=Nanomedicine Editorial Board |url=https://www.futuremedicine.com/journals/nnm/editors?publicationCode=nnm |website=Nanomedicine }}

From 2008 until 2016, he was professor of nanomedicine in the department of pharmacy and professor of pharmaceutical nanotechnology at the Nanoscience Center,{{Cite web |title=Nano-drugs are bad news for diseases|url=https://uniavisen.dk/en/nano-drugs-are-bad-news-for-diseases/|website=University Post|date=30 November 2001 }}{{cite journal |last1=Moghimi |first1=S. Moein |title=Meet Our Editorial Board Member |journal=Current Pharmaceutical Biotechnology |date=2015 |volume=16 |issue=10 |pages=851–852 |doi=10.2174/138920101610150810121628 }} as well as the founder and director of the Centre for Pharmaceutical Nanotechnology and Nanotoxiocology at the University of Copenhagen.{{Cite web |title=Nanotechnology Now - News Story: Denmark funds nanotechnology |url=http://www.nanotech-now.com/news.cgi?story_id=31831 |website=nanotech-now}}{{Cite web |title=Donation for new Center for Pharmaceutical Nanotechnology and Nanotoxicology |url=https://www.eurekalert.org/news-releases/705582|website=EurekAlert!}}

Prior to 2017, Moghimi was professor and chair in pharmaceutics at the Durham University School of Medicine, Pharmacy and Health. Since 2017, he has been professor of Pharmaceutics and Nanomedicine at the School of Pharmacy and Translational and Clinical Research Institute, both part of Newcastle University. He is adjoint professor at the department of pharmaceutical sciences at Skaggs School of Pharmacy, University of Colorado Denver Medical Center.

Moghimi is Editor-in-Chief of the Journal of Nanotheranostics and Drug Delivery.{{Cite journal |date=December 2020|title=The Journal of Nanotheranostics: A New Open-Access Journal at the Interface of Nanotechnology, Materials Science, and Medicine for Precision Medicine |journal=Journal of Nanotheranostics |volume=1 |issue=1 |pages=56–57 |doi=10.3390/jnt1010005 |issn=2624-845X |doi-access=free |last1=Moghimi |first1=S. }} He is associate editor of Precision Nanomedicine, Molecular Therapy,{{Cite web |title=Molecular Therapy editorial board contacts |url=https://www.cell.com/molecular-therapy-family/molecular-therapy/editorial-board |website=Cell.com}} and serves on the editorial boards of journals such as Advanced Drug Delivery Reviews,{{Cite web |title=Editorial board ADDR|url=https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews/about/editorial-board |website=sciencedirect.com}} Journal of Controlled Release,{{Cite web |title=Editorial board - JCR|url=https://www.sciencedirect.com/journal/journal-of-controlled-release/about/editorial-board |website=www.sciencedirect.com}} and Nanomedicine-UK.

Moghimi is known for his work in nanoparticle engineering for biomedical applications, nanosafety, and mechanistic understanding of nanoparticle-mediated complement activation. His research focuses on interdisciplinary approaches to nanotherapies.{{Cite journal |last1=Moghimi |first1=S. Moein |last2=Hunter |first2=A. Christy |last3=Murray |first3=J. Clifford |date=March 2005 |title=Nanomedicine: current status and future prospects |journal=The FASEB Journal |volume=19 |issue=3 |pages=311–330 |doi=10.1096/fj.04-2747rev |doi-access=free |pmid=15746175 |s2cid=30173777 |issn=0892-6638}}{{Cite journal |last1=Moghimi |first1=Seyed M. |last2=Simberg |first2=Dmitri |last3=Anchordoquy |first3=Thomas J. |date=March 2020 |title=Tuning the Engines of Nanomedicine |journal=Molecular Therapy |volume=28 |issue=3 |pages=693–694 |doi=10.1016/j.ymthe.2020.01.025 |pmc=7054826 |pmid=32032534}} Much of his research is related to the management and treatment of chronic conditions associated with population ageing including cancer,{{Cite web |title=Cancer gene therapy from camels |url=https://www.sciencedaily.com/releases/2011/07/110714101511.htm |website=ScienceDaily }} neurological disorders such as Parkinson's disease and Alzheimer's disease, cardiovascular disease, allergies and arthritis.{{cn|date=May 2025}} He specializes in the design and surface engineering of nanosystems and nanoparticles for tissue-specific drug delivery and imaging.{{Cite web |title=Plastic cubes injected into the body could replace booster shots |url=https://www.newscientist.com/article/2147453-plastic-cubes-injected-into-the-body-could-replace-booster-shots/ |website=New Scientist }}{{Cite web |title=Study: How to keep nanoparticle caterpillars safe from the crows of the immune system |url=https://www.eurekalert.org/news-releases/668519 |website=EurekAlert! }}

His current work includes the development of a concomitant long-term computational network assessment of genomics and epigenomic factors in inter-individual variations to nanomedicine performance and cell re-programming.

Resulting from his PhD research, Moghimi introduced the opsonin-dysopsonin hypothesis, suggesting a regulatory role for certain blood proteins in limiting nanoparticle uptake by macrophages.{{Cite journal |date=2020 |title=Opsonins and Dysopsonins of Nanoparticles: Facts, Concepts, and Methodological Guidelines |journal=Frontiers in Immunology |volume=11 |pages=567365|pmid=33154748 |last1=Papini |first1=E. |last2=Tavano |first2=R. |last3=Mancin |first3=F. |doi=10.3389/fimmu.2020.567365 |pmc=7587406 |doi-access=free }} This hypothesis was later applied to highlight multifaceted mechanisms regulating the pharmacokinetic performance of long-circulating drug carriers.{{cite journal |last1=Moghimi |first1=S.M |last2=Patel |first2=H.M |title=Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system – The concept of tissue specificity |journal=Advanced Drug Delivery Reviews |date=June 1998 |volume=32 |issue=1–2 |pages=45–60 |doi=10.1016/s0169-409x(97)00131-2 |pmid=10837635 }}{{cite journal |last1=Moghimi |first1=S.M |last2=Muir |first2=I.S |last3=Illum |first3=L |last4=Davis |first4=S.S |last5=Kolb-Bachofen |first5=V |title=Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum |journal=Biochimica et Biophysica Acta (BBA) - Molecular Cell Research |date=November 1993 |volume=1179 |issue=2 |pages=157–165 |doi=10.1016/0167-4889(93)90137-e |pmid=8218358 }}

Moghimi has developed a range of injectable nanosystems, including an early prototype of splenotropic and lymphotropic nanoparticles based on the concept of steric stabilisation and surface engineering with block copolymers. These concepts are applied for splenic and lymphatic targeting with liposomes and polymeric nanospheres.{{cite journal |last1=Moghimi |first1=S.M. |last2=Porter |first2=C.J.H. |last3=Muir |first3=I.S. |last4=Illum |first4=L. |last5=Davis |first5=S.S. |title=Non-phagocytic uptake of intravenously injected microspheres in rat spleen: Influence of particle size and hydrophilic coating |journal=Biochemical and Biophysical Research Communications |date=June 1991 |volume=177 |issue=2 |pages=861–866 |doi=10.1016/0006-291x(91)91869-e |pmid=2049107 }}{{Cite journal |date=1994-05-09 |title=Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes |journal=FEBS Letters |volume=344 |issue=1 |pages=25–30|pmid=8181558 |last1=Moghimi |first1=S. M. |last2=Hawley |first2=A. E. |last3=Christy |first3=N. M. |last4=Gray |first4=T. |last5=Illum |first5=L. |last6=Davis |first6=S. S. |doi=10.1016/0014-5793(94)00351-3 |s2cid=31767077 |doi-access=free |bibcode=1994FEBSL.344...25M }}

A research group led by Moghimi developed NanoLigand Carriers,{{Cite journal |date=2019-10-11 |title=Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide |journal=Nature Communications |volume=10 |issue=1 |pages=4635|doi=10.1038/s41467-019-12554-2 |pmid=31604928 |last1=Wu |first1=Lin-Ping |last2=Ahmadvand |first2=Davoud |last3=Su |first3=Junan |last4=Hall |first4=Arnaldur |last5=Tan |first5=Xiaolong |last6=Farhangrazi |first6=Z. Shadi |last7=Moghimi |first7=S. Moein |pmc=6789111 |bibcode=2019NatCo..10.4635W }} induced self-assemblies of phage-derived display peptides that on intravenous injection rapidly target two receptors on the blood brain-barrier. On crossing the blood–brain barrier, the carriers target neurons and microglia and deliver their therapeutic nucleic acid payloads to cells. These peptides have applications for the treatment of neurodegenerative disorders.{{Cite web |title=Realising The Potential of Nanomedicine - Formulation & Delivery Approaches |url=https://www.oxfordglobal.co.uk/resources/realising-the-potential-of-nanomedicine-formulation-delivery-approaches/ |website=Oxford Global }}{{Cite web |date=2019-11-12 |title=Beyond the Barrier |url=https://themedicinemaker.com/discovery-development/beyond-the-barrier |website=The Medicine Maker }}

His laboratory was among the first to explain polycation-mediated cell death processes.{{Cite web |title=7 Molecular Therapy classics to read for ASGCT 2017 |url=https://crosstalk.cell.com/blog/7-molecular-therapy-classics-to-read-for-asgct-2017 |website=crosstalk.cell.com }}{{Cite journal |date=June 2006 |title=A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy |journal=Molecular Therapy: The Journal of the American Society of Gene Therapy |volume=11 |issue=6 |pages=990–995|pmid=15922971 |last1=Moghimi |first1=S. M. |last2=Symonds |first2=P. |last3=Murray |first3=J. C. |last4=Hunter |first4=A. C. |last5=Debska |first5=G. |last6=Szewczyk |first6=A. |doi=10.1016/j.ymthe.2005.02.010 |doi-access=free }} Moghimi's laboratory has contributed to the molecular understanding of nanomaterial interactions with elements of the innate immune system and translating these to design immune safe nanoparticles. His laboratory demonstrated the first in vivo assembly of long-circulating and splenotropic nanoparticles without prior surface modification or manipulation of macrophage function,{{cite journal |last1=Moghimi |first1=S.M |title=Prolonging the circulation time and modifying the body distribution of intravenously injected polystyrene nanospheres by prior intravenous administration of poloxamine-908. A 'hepatic-blockade' event or manipulation of nanosphere surface in vivo? |journal=Biochimica et Biophysica Acta (BBA) - General Subjects |date=July 1997 |volume=1336 |issue=1 |pages=1–6 |doi=10.1016/s0304-4165(97)00060-3 |pmid=9271243 }} as well as the first demonstration of the detection of stealth nanoparticles by primed and activated immune cells.{{cite journal |last1=Moghimi |first1=S M |last2=Hedeman |first2=H |last3=Christy |first3=N M |last4=Ilium |first4=L |last5=Davis |first5=S S |title=Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats |journal=Journal of Leukocyte Biology |date=1 December 1993 |volume=54 |issue=6 |pages=513–517 |doi=10.1002/jlb.54.6.513 |pmid=8245702 |s2cid=42780562 }}

This research has involved mapping nanoparticle properties that trigger complement activation and, notably, the role of polymer conformation and hydration in switching complement activation pathways.{{cite journal |last1=Sim |first1=Robert B. |last2=Wallis |first2=Russell |title=Immune attack on nanoparticles |journal=Nature Nanotechnology |date=February 2011 |volume=6 |issue=2 |pages=80–81 |doi=10.1038/nnano.2011.4 |pmid=21293484 |bibcode=2011NatNa...6...80S }} He has resolved some challenging mechanisms modulating complement activation by stealth and polymer-coated nanoparticles.{{cite journal |last1=Salmaso |first1=Stefano |last2=Caliceti |first2=Paolo |title=Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers |journal=Journal of Drug Delivery |date=7 March 2013 |volume=2013 |pages=1–19 |doi=10.1155/2013/374252 |doi-access=free |pmid=23533769 |pmc=3606770 }} His research also explained the molecular basis of complement activation by polyethylene glycol, a polymer that is used widely for prolonging the blood circulation time of proteins and particulate drug carriers.{{cite journal |last1=Hamad |first1=I. |last2=Hunter |first2=A.C. |last3=Szebeni |first3=J. |last4=Moghimi |first4=S.M. |title=Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process |journal=Molecular Immunology |date=December 2008 |volume=46 |issue=2 |pages=225–232 |doi=10.1016/j.molimm.2008.08.276 |pmid=18849076 }}{{cite journal |last1=de Vrieze |first1=Jop |title=Suspicions grow that nanoparticles in Pfizer's COVID-19 vaccine trigger rare allergic reactions |journal=ScienceInsider |date=8 March 2021 |doi=10.1126/science.abg2359 }}

His lab was the first to demonstrate tumour growth promotion by stealth nanoparticles through local nanoparticle-mediated complement activation,{{cite journal |last1=Moghimi |first1=S.M. |title=Cancer nanomedicine and the complement system activation paradigm: Anaphylaxis and tumour growth |journal=Journal of Controlled Release |date=September 2014 |volume=190 |pages=556–562 |doi=10.1016/j.jconrel.2014.03.051 |pmid=24746624 }} and developed the first complement-evading hexosomes.{{cite journal |last1=Wibroe |first1=Peter P. |last2=Mat Azmi |first2=Intan D. |last3=Nilsson |first3=Christa |last4=Yaghmur |first4=Anan |last5=Moghimi |first5=S. Moein |title=Citrem modulates internal nanostructure of glyceryl monooleate dispersions and bypasses complement activation: Towards development of safe tunable intravenous lipid nanocarriers |journal=Nanomedicine |date=November 2015 |volume=11 |issue=8 |pages=1909–1914 |doi=10.1016/j.nano.2015.08.003 |pmid=26348655 }}

He has challenged the validity of the CARPA (Complement Activation Related Pseudo-Allergy) hypothesis, and proposed a working mechanism explaining idiosyncratic nanomedicine-mediated anaphylaxis seen in patients.{{cite journal |last1=Wibroe |first1=Peter Popp |last2=Anselmo |first2=Aaron C. |last3=Nilsson |first3=Per H. |last4=Sarode |first4=Apoorva |last5=Gupta |first5=Vivek |last6=Urbanics |first6=Rudolf |last7=Szebeni |first7=Janos |last8=Hunter |first8=Alan Christy |last9=Mitragotri |first9=Samir |last10=Mollnes |first10=Tom Eirik |last11=Moghimi |first11=Seyed Moein |title=Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes |journal=Nature Nanotechnology |date=June 2017 |volume=12 |issue=6 |pages=589–594 |doi=10.1038/nnano.2017.47 |pmid=28396605 |bibcode=2017NatNa..12..589W |hdl=10037/13642 |url=https://cdr.lib.unc.edu/downloads/2f75rj54s |hdl-access=free }}{{cite journal |last1=Moghimi |first1=Seyed Moein |title=Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions |journal=Drug Discovery Today |date=May 2018 |volume=23 |issue=5 |pages=1034–1042 |doi=10.1016/j.drudis.2017.11.006 |pmid=29146517 }} Moghimi also introduced the nanomaterial projected "Angstrom-Scale Spacing Arrangement" hypothesis, in modulating complement system responses to nanomedicines and medical implants.{{cite journal |last1=Wu |first1=Lin-Ping |last2=Ficker |first2=Mario |last3=Christensen |first3=Jørn B. |last4=Simberg |first4=Dmitri |last5=Trohopoulos |first5=Panagiotis N. |last6=Moghimi |first6=Seyed M. |title=Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking |journal=Nature Communications |date=11 August 2021 |volume=12 |issue=1 |page=4858 |doi=10.1038/s41467-021-24960-6 |pmid=34381048 |pmc=8357934 |bibcode=2021NatCo..12.4858W }}

In 2020, Moghimi commented on the sudden closure of the Centers of Cancer Nanotechnology Excellence in the United States, and called for support in curiosity driven research in fundamental nanomedicine even in the absence of immediate obvious benefits to society.{{Cite journal |title=Tuning the Engines of Nanomedicine |journal=Molecular Therapy |date=2020 |volume=28 |issue=3 |pages=693–694|doi=10.1016/j.ymthe.2020.01.025 |pmid=32032534 |last1=Moghimi |first1=S. M. |last2=Simberg |first2=D. |author3=Anchordoquy TJ |pmc=7054826 }}

• {{Cite book |title=Handbook of Clinical Nanomedicine |publisher=Pan Stanford Publishing |year=2016 |isbn=9789814669221 |edition=2nd |chapter=Nanomedicine: Shadow and substance}}. With Fahrangrazi, Shadi.
• {{Cite book |title=Polymer-Based Nanostructures: Medical Applications |publisher=Royal Society of Chemistry |series=RCS Nanoscience and Nanotechnology Series|year=2010 |isbn=9780854049561 |chapter=Particle Nanoengineering for the Lymphatic System and Lymph Node Targeting}}

• {{Cite journal |date=June 2017 |title=Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes |url=https://cdr.lib.unc.edu/downloads/2f75rj54s |journal=Nature Nanotechnology |volume=12 |issue=6 |pages=589–594 |doi=10.1038/nnano.2017.47 |issn=1748-3395 |last1=Wibroe |first1=Peter Popp |last2=Anselmo |first2=Aaron C. |last3=Nilsson |first3=Per H. |last4=Sarode |first4=Apoorva |last5=Gupta |first5=Vivek |last6=Urbanics |first6=Rudolf |last7=Szebeni |first7=Janos |last8=Hunter |first8=Alan Christy |last9=Mitragotri |first9=Samir |last10=Mollnes |first10=Tom Eirik |last11=Moghimi |first11=Seyed Moein |pmid=28396605 |bibcode=2017NatNa..12..589W |hdl=10037/13642 |hdl-access=free }}
• {{Cite journal |date=April 2017 |title=Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo |journal=Nature Nanotechnology |volume=12 |issue=4 |pages=387–393 |doi=10.1038/nnano.2016.269 |issn=1748-3395 |last1=Chen |first1=Fangfang |last2=Wang |first2=Guankui |last3=Griffin |first3=James I. |last4=Brenneman |first4=Barbara |last5=Banda |first5=Nirmal K. |last6=Holers |first6=V. Michael |last7=Backos |first7=Donald S. |last8=Wu |first8=Linping |last9=Moghimi |first9=Seyed Moein |last10=Simberg |first10=Dmitri |pmid=27992410 |pmc=5617637 |bibcode=2017NatNa..12..387C }}
• {{cite journal |last1=Moghimi |first1=S. M. |last2=Hunter |first2=A. C. |last3=Murray |first3=J. C. |title=Long-circulating and target-specific nanoparticles: theory to practice |journal=Pharmacological Reviews |date=June 2001 |volume=53 |issue=2 |pages=283–318 |doi=10.1016/S0031-6997(24)01494-7 |pmid=11356986 }}
• {{Cite journal |date=2005 |title=Nanomedicine: current status and future prospects |journal=FASEB Journal|volume=19 |issue=3 |pages=311–330|pmid=15746175 |last1=Moghimi |first1=S. M. |last2=Hunter |first2=A. C. |last3=Murray |first3=J. C. |doi=10.1096/fj.04-2747rev |doi-access= free|s2cid=30173777 }}
• {{Cite journal |date=2005 |title=A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy |journal=Molecular Therapy|volume=11 |issue=6 |pages=990–995|pmid=15922971 |last1=Moghimi |first1=S. M. |last2=Symonds |first2=P. |last3=Murray |first3=J. C. |last4=Hunter |first4=A. C. |last5=Debska |first5=G. |last6=Szewczyk |first6=A. |doi=10.1016/j.ymthe.2005.02.010 |doi-access=free }}
• {{cite journal |last1=Hamad |first1=I. |last2=Hunter |first2=A.C. |last3=Szebeni |first3=J. |last4=Moghimi |first4=S.M. |title=Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process |journal=Molecular Immunology |date=December 2008 |volume=46 |issue=2 |pages=225–232 |doi=10.1016/j.molimm.2008.08.276 |pmid=18849076 }}
• {{cite journal |last1=Hamad |first1=Islam |last2=Al-Hanbali |first2=Othman |last3=Hunter |first3=A. Christy |last4=Rutt |first4=Kenneth J. |last5=Andresen |first5=Thomas L. |last6=Moghimi |first6=S. Moein |title=Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways at the Nanosphere−Serum Interface: Implications for Stealth Nanoparticle Engineering |journal=ACS Nano |date=23 November 2010 |volume=4 |issue=11 |pages=6629–6638 |doi=10.1021/nn101990a |pmid=21028845 |url=https://cris.brighton.ac.uk/ws/files/236607/Hunter_Rutt_Distinct_polymer.pdf }}
• {{Cite journal |date=2019 |title=Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide |journal=Nature Communications |volume=10 |issue=1 |pages=4635|doi=10.1038/s41467-019-12554-2 |pmid=31604928 |last1=Wu |first1=Lin-Ping |last2=Ahmadvand |first2=Davoud |last3=Su |first3=Junan |last4=Hall |first4=Arnaldur |last5=Tan |first5=Xiaolong |last6=Farhangrazi |first6=Z. Shadi |last7=Moghimi |first7=S. Moein |pmc=6789111 |bibcode=2019NatCo..10.4635W }}
• {{Cite journal |date=2021 |title=Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking |journal=Nature Communications |volume=12 |issue=1 |pages=4858|pmid=34381048 |last1=Wu |first1=L. P. |last2=Ficker |first2=M. |last3=Christensen |first3=J. B. |last4=Simberg |first4=D. |last5=Trohopoulos |first5=P. N. |last6=Moghimi |first6=S. M. |doi=10.1038/s41467-021-24960-6 |pmc=8357934 |bibcode=2021NatCo..12.4858W }}

• {{ORCID|0000-0003-0836-926X}}
• {{Google Scholar ID|id=hK1RM-4AAAAJ|name=Moein Moghimi}}
• [https://www.ncl.ac.uk/pharmacy/people/profile/seyedmoghimi.html Professor Moein Moghimi] at ncl.ac.uk

{{reflist}}

{{Authority control}}

{{DEFAULTSORT:Moghimi, Moein}}

Category:British biochemists

Category:British nanotechnologists

Category:Academics of Newcastle University

Category:Academics of the University of Brighton

Category:Academic staff of the University of Copenhagen

Category:Alumni of the University of Manchester

Category:Alumni of Charing Cross Medical School

Category:Iranian emigrants to England

Category:University of Colorado Denver faculty

Category:Year of birth missing (living people)

Category:Living people